Drug Database
RA

rabies immunoglobulin (human) (HyperRAB S/D)

✓ Approved

Grifols, S.A. · 多克隆抗体 · 多克隆抗体

什么是 rabies immunoglobulin (human)?

rabies immunoglobulin (human) 是一种多克隆抗体,由Grifols, S.A.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名HyperRAB S/D
公司Grifols, S.A.
药物类别多克隆抗体, 抗体
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

治疗适应症

rabies immunoglobulin (human) 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsRabies✓ Approved

相关研究文献

PubMedEuropean journal of rheumatology2026-11-18

Coincidence of Mixed Connective Tissue Disease with Immunoglobulin G4-Related Disease: A Case Report.

Kocaayan Hasan H, Ediboglu Elif Durak ED, Aydin Ilgin I, Erdogan Nezahat N et al.

Immunoglobulin G4-related disease (IgG4-RD) is an immune-mediated fibroinflammatory disorder characterized by mass forming lesions that can result in irreversible organ damage and mortality if ignored. Mixed connective tissue disease (MCTD) is characterized as an overlap of systemic lupus erythematosus (SLE), systemic sclerosis, inflammatory myopathy, and rheumatoid arthritis (RA). While cases of IgG4-RD linked to SLE and RA have been documented, to the authors' knowledge, there has not been a recorded instance of a patient with IgG4-RD related with MCTD. A patient diagnosed with both MCTD and IgG4-RD is presented.   Cite this article as: Kocaayan H, Ediboglu ED, Aydin I, Erdogan N, Akar S. Coincidence of mixed connective tissue disease with immunoglobulin -related disease: A case report. Eur J Rheumatol. 2025, 12 (4), 0043, doi: 10.5152/ eurjrheum.2025.25043.

PMID 43049124
阅读全文 →
PubMedBioconjugate chemistry2026-11-18

Characterization and Optimization of Monobody Proteins for Targeting of Polymeric Nanoparticles to Endothelial Cells.

Harkins Lauren L, Solomon Abigail A, Zhang Xianzhi X, Koide Akiko A et al.

The conjugation of antibodies (Abs) to nanoparticles (NPs) is often used to target NPs to specific cell populations. However, there are issues with the methods of Ab attachment to the NP, and the effectiveness of the targeting varies with different conjugation methods. Site-specific conjugation of monobody (Mb) proteins to NPs help address the effectiveness of Ab attachment by controlling the Ab orientation on the NPs to improve targeting to cells. Here, we expand upon previous work showing the effectiveness of the Mb attachment system by providing a more in-depth characterization of Mb proteins. We investigated impacts on NP stability and in vitro cell binding of protein amounts (Mb and Ab), different Mb proteins (targeting mouse immunoglobulin G1 and human intercellular adhesion molecule 2), polymeric NP types (based on polylactic acid and poly amine-co-ester), and a conjugation method optimization. The results suggest that while Mb proteins are effective in targeting NPs to cells, different Mb proteins and different polymer NPs have different binding and stability profiles, highlighting the importance of characterization when adapting the system to NPs of different chemistry.

PMID 43046851
阅读全文 →
PubMedBiomaterials research2026-11-18

Multilamellar Nanovaccine for Enhanced Anti-Staphylococcus aureus Immunity and Bacterial Clearance.

Chung Yun Shin YS, Lee Dong Jae DJ, Kim Hee Seung HS, Seo Jong Hyeon JH et al.

Staphylococcus aureus infections pose a serious public health threat due to increasing antibiotic resistance, pointing to the need for an effective vaccine. Here, we developed a multilamellar protein-lipid hybrid nanovaccine, termed CDMH, consisting of the S. aureus clumping factor A (ClfAN23) electrostatically self-assembled with cationic DOTAP lipid vesicles, followed by the incorporation of monophosphoryl lipid A and hyaluronic acid as an immunostimulatory adjuvant and a stabilizing surface polymer, respectively. This conjugation-free multilamellar structure was designed to enhance antigen protection, codelivery with an adjuvant, and uptake by antigen-presenting cells. In mice, CDMH immunization induced strong cellular immunity characterized by robust CD4+ T-cell proliferation, particularly interleukin-17A-producing T helper 17 (Th17) cells, along with elevated ClfAN23-specific immunoglobulin G and immunoglobulin M levels. The multilamellar architecture improved antigen-adjuvant codelivery, promoting the recruitment of reactive-oxygen-species-producing macrophages at infection sites and thereby enhancing bacterial clearance following S. aureus challenge. These findings indicate that CDMH promotes coordinated humoral and cellular immune responses, including Th17 polarization, antigen-specific antibody production, and macrophage-associated phagocyte activation, which are associated with enhanced early bacterial clearance in vivo. This study suggests a multilamellar codelivery strategy as a modular design principle for shaping antigen-specific immune quality against extracellular bacterial pathogens.

PMID 43047806
阅读全文 →
PubMedCureus2026-11-18

A Cold and Viscous Clue: Waldenström Macroglobulinemia Presenting With Secondary Cold Agglutinin Syndrome and Hyperviscosity Syndrome.

Chuang Fukai L FL, Huynh Julie J, Alcantar Juan M JM, Kim David D DD

Waldenström macroglobulinemia (WM) is an indolent mature B-cell lymphoproliferative disorder defined by bone marrow infiltration by lymphoplasmacytic lymphoma (LPL) and an associated serum monoclonal immunoglobulin M (IgM) gammopathy. In this case report, we describe a patient presenting with two serious and rare IgM-mediated complications of WM that require urgent treatment: secondary cold agglutinin syndrome and hyperviscosity syndrome. With prompt diagnosis and therapeutic plasma exchange, the patient's IgM-mediated complications improved, with a marked reduction in serum IgM and resolution of hyperviscosity-related symptoms. This highlights the importance of recognizing the possible complications of an otherwise indolent disease.

PMID 43048389
阅读全文 →
PubMedFrontiers in immunology2026-11-18

Higher observed 12-month relapse-free survival with satralizumab than with rituximab in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder: a multicenter retrospective cohort study.

Lin Xiao X, Zhang Jicheng J, Chen Lei L, Deng Meiqun M et al.

Direct real-world comparisons of satralizumab and rituximab in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder remain uncommon. We conducted a multicenter retrospective cohort study across eight hospitals in Fujian Province, China. Patients aged 12 years or older contributed treatment episodes beginning at the first verifiable administration of satralizumab or rituximab. Patients who changed therapy could contribute one episode to each treatment group, while uncertainty estimates accounted for patient-level clustering. The primary outcome was time to the first clinician-documented NMOSD relapse. Kaplan-Meier methods estimated 12-month relapse-free survival and its absolute between-treatment difference. Restricted mean relapse-free time, recurrent relapses, treatment-period safety events, and exploratory Expanded Disability Status Scale outcomes were also examined. Sensitivity analyses considered treatment switching, episode selection, calendar era, center composition, age restriction, and propensity-score overlap weighting. The cohort included 103 patients and 115 treatment episodes (50 satralizumab and 65 rituximab). First relapse within 12 months occurred in 1 satralizumab episode and 10 rituximab episodes. Twelve-month relapse-free survival was 98.0% (95% CI, 94.2-100.0%) with satralizumab and 84.6% (95% CI, 76.2-93.8%) with rituximab, an absolute difference of 13.44 percentage points (patient-clustered bootstrap 95% CI, 4.20-23.59). The direction was consistent across the principal unweighted sensitivity analyses. Corrected overlap weighting yielded a 5.28-percentage-point difference (95% CI, -11.69 to 21.21); limited common support, an effective rituximab sample size of 9.38, and appreciable patient influence made this an exploratory estimate. Infection rates were 18.2 and 14.7 events per 100 treatment-episode years, respectively (rate ratio, 1.24; 95% CI, 0.58-2.37), and one serious adverse event occurred in each group. Exploratory EDSS analyses did not identify a clear between-group difference. Satralizumab episodes had higher observed 12-month relapse-free survival than rituximab episodes in this cohort. The finding is a clinically relevant real-world comparison signal, while the treatment-specific contribution to the difference remains uncertain because treatment eras were separated, common support was limited, and satralizumab events were sparse.

PMID 43047378
阅读全文 →
PubMedClinical medicine insights. Arthritis and musculoskeletal disorders2026-11-18

Successful Anifrolumab Treatment for Refractory Skin Lesions in Monogenic Lupus Due to C1R Deficiency.

Alisan Aybuke A, Akay Nergis N, Ekinci Rabia Miray Kisla RMK, Yildiz Mehmet M et al.

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease exhibiting clinical heterogeneity among affected individuals. In monogenic lupus, which results from single-gene mutations, there is an early onset, atypical and severe course, and usually a familial predisposition. One of the common causes of monogenic SLE is deficiencies in the early components of the classical pathway of the complement system. We present here a 9-year-old male with hereditary C1R deficiency, suffering from chronic discoid rash since the age of 18 months, who did not sufficiently respond to conventional treatment, including topical and systemic steroids, hydroxychloroquine, mycophenolate mofetil, intravenous immunoglobulin, and baricitinib. Subsequently, the skin findings improved after the initiation of anifrolumab, an anti-IFNAR antibody. To the best of our knowledge, this report represents the first successful treatment of monogenic lupus and C1R deficiency with anifrolumab in the literature.

PMID 43048400
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多rabies immunoglobulin (human)